Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gloucester’s NDA For Romidepsin In CTCL Is Targeted For Submission By Year End

This article was originally published in The Pink Sheet Daily

Executive Summary

Company will present pivotal trial data on the HDAC inhibitor at the American Society of Hematology in December.

You may also be interested in...

MethylGene Revamps Pipeline As Celgene Backs Off HDAC, Sirtuin Collaboration

Firm has high hopes for lifting the clinical hold on MGDC0103.

Gloucester Pharmaceuticals Inc.

Two subtypes of T-cell mediated lymphomas have been very difficult to treat using the existing cytotoxic chemotherapy treatments. CTCL and peripheral T-cell lymphoma (PTCL) patients receiving chemotherapy may experience severe, dose-limiting toxicities and develop resistance to the therapy. Gloucester Pharmaceuticals Inc. is developing a treatment that potentially is more effective than chemo, the company says, and the National Institutes of Health is backing its development.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts